What is AKBA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.22B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AKBA?

P/E (TTM) is n/a and 52-week range is $0.80 to $3.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AKBA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AKBA?

The company profile lists revenue (TTM) near $218M, net income (TTM) near $-2.95B, EPS (TTM) near $-0.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Akebia Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 268.3M shares outstanding, ISIN US00972D1054 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Akebia Therapeutics Inc

$AKBA

Health Care · Biotechnology

IR Run Scenarios

$0.80

-1.68%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2014-03-20. The firm's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The firm's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Employees

194

Website

akebia.com/

IPO

2014-03-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)